NEUBASE THERAPEUTICS, INC. OHRP Balance Sheet

Neubase therapeutics, inc. (OHRP)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Sep'10
Assets
CURRENT ASSETS
Cash and cash equivalents
5,800	7,730	10,313	1,424	2,129	3,110	249	4,435	5,215	8,724	12,801	18,079	9,521	13,489	12,546	17,623	21,881	25,325	28,697	30,979	32,823	10,441	13,220	14,878	3,474	4,016	5,122	6,048	1,765	2,068	2,632	1,445	775	1,262	469	878	422
Prepaid insurance
239	339	449	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
196	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other prepaid expenses and current assets
260	462	265	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	133	202	103	-	413	622	100	223	436	570	371	738	231	456	1,777	338	724	765	579	133	189	236	19	45	212	208	210	218	463	441	78	37	31	34
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	179	0	65
Security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	85
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	5	-	0
Total Current Assets
6,469	8,532	11,029	1,558	2,331	3,213	249	4,848	5,837	8,824	13,024	18,516	10,091	13,860	13,285	17,855	22,337	27,103	29,036	31,704	33,589	11,020	13,354	15,095	3,711	4,036	5,168	6,260	1,974	2,279	2,850	1,908	1,216	1,341	691	910	607
EQUIPMENT, net
536	471	430	12	15	13	-	18	20	60	63	79	172	187	198	214	229	244	248	259	166	96	104	196	23	26	29	36	38	40	43	45	47	50	19	20	24
OTHER ASSETS
Security deposit
-	-	-	-	-	-	-	-	-	0	12	12	12	12	12	12	12	12	12	12	12	12	12	12	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	35	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible assets, net
0	20	145	7,122	7,285	7,446	-	13,205	13,529	13,805	14,087	14,369	14,648	14,925	15,208	15,490	15,770	16,050	16,332	16,615	16,895	17,512	17,810	17,840	-	-	545	565	584	604	-	-	-	-	-	-	-
Investment
469	561	586	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term prepaid insurance
242	290	338	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Assets
711	873	1,071	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill
-	-	-	-	-	-	-	-	-	740	740	740	740	740	740	740	740	740	740	740	740	740	740	2,409	-	-	-	-	-	-	-	-	-	-	-	-	-
Patent costs, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	507	526	-	-	-	-	623	643	662	682	701	721	780
TOTAL ASSETS
7,716	9,877	12,531	8,692	9,631	10,674	249	18,071	19,387	23,432	27,928	33,718	25,665	29,726	29,445	34,313	39,090	44,151	46,370	49,337	51,439	29,382	32,025	35,553	4,242	4,589	5,743	6,861	2,597	2,924	3,517	2,597	1,926	2,073	1,412	1,652	1,412
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable
1,664	1,366	1,477	-	-	-	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other current liabilities
942	242	405	-	-	-	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liabilities
1,120	1,190	496	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	751	624	597	-	706	1,444	3,598	4,827	5,435	6,780	3,886	4,394	3,627	1,869	2,540	1,592	1,877	1,320	1,192	351	294	720	250	465	211	314	204	300	292	313	317	301	325	338
Due to Joint Venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued salaries
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Insurance note payable
0	49	122	-	-	-	-	181	287	0	106	158	261	0	87	130	215	0	48	119	189	0	43	108	194	0	14	42	3	7	22	44	48	-	-	0	17
Contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,535	1,430	2,736	2,239	1,753	1,774	5,560	4,877	6,362	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	51
Derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,171	768	2,084	2,258	5,208	5,893	-	1,387
Total Current Liabilities
-	-	-	751	624	597	41	888	1,732	3,598	4,933	5,594	7,042	3,886	4,481	5,293	3,515	5,276	3,880	3,750	3,283	6,776	5,273	6,766	914	250	479	254	317	2,383	1,091	2,420	2,620	5,525	6,194	325	1,794
LONG-TERM LIABILITIES
Convertible notes payable, net
-	-	-	-	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term liabilities
-	-	-	-	-	-	-	-	-	150	150	150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock warrant derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,861	-
Total Long-term Liabilities
-	-	-	-	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,861	-
Total Liabilities
3,727	2,849	2,502	751	624	597	291	888	1,732	3,748	5,083	5,744	7,042	3,886	4,481	5,293	3,515	5,276	3,880	3,750	3,283	6,776	5,273	6,766	914	250	479	254	317	2,383	1,091	2,420	2,620	5,525	6,194	5,186	1,794
COMMITMENTS AND CONTINGENCIES
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and September 30, 2019
0	0	0	-	-	-	-	0	0	0	-	0	-	-	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.0001 par value; 250,000,000 shares authorized; 17,080,625 and 17,077,873 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively
1	1	1	0	0	0	0	5	5	5	5	5	3	3	3	3	3	3	3	3	2	2	2	2	2	1	1	1	4	4	1	4	4	4	3	3	3
Additional paid-in capital
39,871	38,532	37,027	132,440	132,373	132,299	-0	132,147	132,074	131,917	130,927	130,812	117,563	117,090	109,237	106,658	105,514	103,528	100,999	100,185	99,407	70,515	70,063	69,009	41,498	40,541	39,444	38,985	33,314	31,283	30,966	30,585	27,438	23,318	22,289	22,178	21,587
Stock subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	11	1,815	-	50	0	-	-
Accumulated deficit
-35,884	-31,505	-27,000	-124,499	-123,366	-122,223	-41	-114,969	-114,424	-112,239	-108,088	-102,844	-98,943	-91,253	-84,277	-77,641	-69,941	-64,656	-58,511	-54,601	-51,255	-47,911	-43,313	-40,225	-21,628	-21,628	-34,182	-21,628	-21,628	-21,628	-21,628	-21,628	-21,628	-21,628	-21,628	-21,628	-21,628
Deficit accumulated during the development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,544	14,576	-	10,750	9,412	9,120	6,901	6,969	6,508	5,096	5,446	4,088	345
Total stockholders' equity
3,989	7,028	10,029	7,941	9,007	10,076	-41	17,183	17,655	19,683	22,844	27,974	18,623	25,840	24,963	29,020	35,575	38,874	42,490	45,587	48,155	22,606	26,752	28,787	3,327	4,338	5,264	6,607	2,279	540	2,426	177	-693	-3,451	-4,781	-3,534	-382
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
7,716	9,877	12,531	8,692	9,631	10,674	249	18,071	19,387	23,432	27,928	33,718	25,665	29,726	29,445	34,313	39,090	44,151	46,370	49,337	51,439	29,382	32,025	35,553	4,242	4,589	5,743	6,861	2,597	2,924	3,517	2,597	1,926	2,073	1,412	1,652	1,412